Ľubomíra Fábryová
Strategies for preventing complications of atherosclerotic vascular disease have emphasized risk factor modification using treatment approaches supported by evidence based medicine (aspirin and/or clopidogrel, β-adrenergic blockers, angiotensin-converting enzyme inhibitors and statins). Despite the intensive management of conventional risk factors of atherosclerosis, residual cardiovascular and cerebrovascular risk remains high. All this is leading to the effort to influence the prognosis of high risk patients by the development of new hypolipidemics which can be targeted to influence atherogenic lipoproteins (squalene synthase inhibitors, MTP inhibitors, antisense oligonucleotides to apo B, anti PCSK9 monoclonal antibodies) as well as to target the metabolism of antiatherogenic high density lipoproteins (CETP inhibitors, LX receptor agonists, PPAR-α agonists, PPAR-β/δ agonists, endothelial lipase inhibitors, Apo A-I mimetic peptides).